{
  "url": "https://openlegislation.uk/eu-regulation-2015-1221/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-2015-1221/annex.json",
  "legislation": "eur/2015/1221",
  "legislation_title": "Commission Regulation (EU) 2015/1221 of 24 July 2015 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures, for the purposes of its adaptation to technical and scientific progress (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2015-1221",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": null,
  "text": "Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:\n(1) Table 3.1 is amended as follows:\n(a) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:\nIndex No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n007-004-00-1\nnitric acid … %\n231-714-2\n7697-37-2\nOx. Liq. 2\nSkin Corr. 1A\nH272\nH314\nGHS03\nGHS05\nDgr\nH272\nH314\nEUH071\nSkin Corr. 1A; H314: C ≥ 20 %\nSkin Corr. 1B; H314: 5 % ≤ C < 20 %\nOx. Liq. 2; H272: C ≥ 99 %\nOx. Liq. 3; H272: 99 % > C ≥ 65 %\nB\n015-003-00-2\ncalcium phosphide; tricalcium diphosphide\n215-142-0\n1305-99-3\nWater-react. 1\nAcute Tox. 2\nAcute Tox. 3\nAcute Tox. 1\nEye Dam. 1\nAquatic Acute 1\nH260\nH300\nH311\nH330\nH318\nH400\nGHS02\nGHS06\nGHS05\nGHS09\nDgr\nH260\nH300\nH311\nH330\nH318\nH400\nEUH029\nEUH032\nM = 100\n031-001-00-4\ngallium arsenide\n215-114-8\n1303-00-0\nRepr. 1B\nCarc. 1B\nSTOT RE 1\nH360F\nH350\nH372 (respiratory and haematopoietic systems)\nGHS08\nDgr\nH360F\nH350\nH372 (respiratory and haematopoietic systems)\n050-008-00-3\ntributyltin compounds, with the exception of those specified elsewhere in this annex\n—\n—\nRepr. 1B\nAcute Tox. 3\nAcute Tox. 4*\nSTOT RE 1\nSkin Irrit. 2\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH360FD\nH301\nH312\nH372**\nH315\nH319\nH400\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH360FD\nH301\nH312\nH372**\nH315\nH319\nH410\n*\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,25 % ≤ C < 1 %\nSkin Irrit. 2; H315:C ≥ 1 %\nEye Irrit. 2; H319:C ≥ 1 %\nM = 10\nA\n1\n603-102-00-9\n1,2-epoxybutane\n203-438-2\n106-88-7\nFlam. Liq. 2\nCarc. 2\nAcute Tox. 4*\nAcute Tox. 4*\nAcute Tox. 4*\nSTOT SE 3\nSkin Irrit. 2\nEye Irrit. 2\nH225\nH351\nH302\nH312\nH332\nH335\nH315\nH319\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH351\nH302\nH312\nH332\nH335\nH315\nH319\n603-197-00-7\ntebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol\n403-640-2\n107534-96-3\nRepr. 2\nAcute Tox. 4\nAquatic Acute 1\nAquatic Chronic 1\nH361d***\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361d***\nH302\nH410\nM = 1\nM = 10\n606-054-00-7\nisoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone\n—\n141112-29-0\nRepr. 2\nAquatic Acute 1\nAquatic Chronic 1\nH361d***\nH400\nH410\nGHS08\nGHS09\nWng\nH361d***\nH410\nM = 10\nM = 100\n607-197-00-8\nnonanoic acid\n203-931-2\n112-05-0\nSkin Irrit. 2\nEye Irrit. 2\nAquatic Chronic 3\nH315\nH319\nH412\nGHS07\nWng\nH315\nH319\nH412\n613-042-00-5\nimazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole\n252-615-0\n35554-44-0\nCarc. 2\nAcute Tox. 3\nAcute Tox. 4\nEye Dam. 1\nAquatic Chronic 1\nH351\nH301\nH332\nH318\nH410\nGHS08\nGHS06\nGHS05\nGHS09\nDgr\nH351\nH301\nH332\nH318\nH410\nM = 10\n613-057-00-7\ndodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine\n216-474-9\n1593-77-7\nRepr. 2\nSTOT RE 2\nSkin Corr. 1C\nSkin Sens. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH373 (liver)\nH314\nH317\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH361d\nH373 (liver)\nH314\nH317\nH410\nEUH071\nM = 1\nM = 1\n613-133-00-X\netridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole\n219-991-8\n2593-15-9\nCarc. 2\nAcute Tox. 4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH317\nH410\nM = 1\nM = 1\n613-149-00-7\npyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one\n405-700-3\n96489-71-3\nAcute Tox. 3\nAcute Tox. 3\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH301\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH301\nH410\nM = 1 000\nM = 1 000\n(b) the following entries are inserted in accordance with the order of the entries set out in Table 3.1:\nIndex No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n019-003-00-3\npotassium (E,E)-hexa-2,4-dienoate\n246-376-1\n24634-61-5\nEye Irrit. 2\nH319\nGSH07\nWng\nH319\n604-092-00-9\nphenol, dodecyl-, branched [1];\nphenol, 2-dodecyl-, branched;\nphenol, 3-dodecyl-, branched;\nphenol, 4-dodecyl-, branched;\nphenol, (tetrapropenyl) derivatives [2]\n310-154-3 [1]\n121158-58-5 [1]\n74499-35-7 [2]\nSkin Corr. 1C\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\nM = 10\nM = 10\n606-148-00-8\ncarvone (ISO);\n2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]\nd-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]\nl-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]\n202-759-5 [1]\n218-827-2 [2]\n229-352-5 [3]\n99-49-0 [1]\n2244-16-8 [2]\n6485-40-1 [3]\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n606-149-00-3\ntembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione\n—\n335104-84-2\nRepr. 2\nSTOT RE 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH373 (eyes, kidneys, liver)\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361d\nH373 (eyes, kidneys, liver)\nH317\nH410\nM = 100\nM = 10\n607-707-00-9\nfenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate\n—\n71283-80-2\nSTOT RE 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373 (kidneys)\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH373 (kidneys)\nH317\nH410\nM = 1\nM = 1\n607-708-00-4\noctanoic acid\n204-677-5\n124-07-2\nSkin Corr. 1C\nAquatic Chronic 3\nH314\nH412\nGHS05\nDgr\nH314\nH412\n607-709-00-X\ndecanoic acid\n206-376-4\n334-48-5\nSkin Irrit. 2\nEye Irrit. 2\nAquatic Chronic 3\nH315\nH319\nH412\nGHS07\nWng\nH315\nH319\nH412\n607-710-00-5\n1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear\n271-093-5\n68515-50-4\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\n607-711-00-0\nspirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate\n—\n203313-25-1\nRepr. 2\nSTOT SE 3\nEye Irrit. 2\nSkin Sens. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH361fd\nH335\nH319\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361fd\nH335\nH319\nH317\nH410\nM = 1\nM = 1\n607-712-00-6\ndodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate\n250-778-2\n31717-87-0\nRepr. 2\nSTOT RE 2\nSkin Corr. 1C\nSkin Sens. 1A\nAquatic Chronic 1\nH361d\nH373 (liver)\nH314\nH317\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH361d\nH373 (liver)\nH314\nH317\nH410\nEUH071\nM = 1\n607-713-00-1\nfenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate\n—\n134098-61-6\nAcute Tox. 3\nAcute Tox. 2\nSkin Sens. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH330\nH317\nH400\nH410\nGHS06 GHS09\nDgr\nH301\nH330\nH317\nH410\nM = 100\nM = 1 000\n607-714-00-7\ntriflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate\n—\n126535-15-7\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\nM = 100\nM = 10\n607-715-00-2\nbifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate\n442-820-5\n149877-41-8\nSTOT RE 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH373\nH317\nH410\nM = 1\nM = 1\n613-319-00-0\nimidazole\n206-019-2\n288-32-4\nRepr. 1B\nAcute Tox. 4\nSkin Corr. 1C\nH360D\nH302\nH314\nGHS08\nGHS07\nGHS05\nDgr\nH360D\nH302\nH314\n613-320-00-6\nlenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione\n218-499-0\n2164-08-1\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\nM = 10\nM = 10\n616-213-00-2\nmandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide\n—\n374726-62-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1\nM = 1\n616-214-00-8\nmetosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide\n—\n139528-85-1\nCarc. 2\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH373 (eyes, kidneys)\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH373 (eyes, kidneys)\nH410\nM = 1 000\nM = 100\n616-215-00-3\ndimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide\n—\n163515-14-8\nAcute Tox. 4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\nM = 10\nM = 10\n616-216-00-9\nflonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide\n—\n158062-67-0\nAcute Tox. 4\nH302\nGHS07\nWng\nH302\n616-217-00-4\nsulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide\n—\n946578-00-3\nAcute Tox. 4\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM = 1\nM = 1\n(2) Table 3.2 is amended as follows:\n(a) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:\nIndex No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nConcentration Limits\nNotes\n007-004-00-1\nnitric acid … %\n231-714-2\n7697-37-2\nO; R8\nC; R35\nO; C\nR: 8-35\nS: (1/2-)26-28- 36/37/39-45-63\nO; R8: C ≥ 65 %\nC; R35: C ≥ 20 %\nC; R34: 5 % ≤ C < 20 %\nB\n015-003-00-2\ncalcium phosphide; tricalcium diphosphide\n215-142-0\n1305-99-3\nF; R15/29\nT+; R26/28\nXn; R21\nR32\nXi; R38-41\nN; R50\nF; T+; N\nR: 15/29-21-26/28-32-38-41-50\nS:(1/2-)26-28-30-36/37/39-43-45-60-61\nN; R50: C ≥ 0,25 %\n031-001-00-4\ngallium arsenide\n215-114-8\n1303-00-0\nRepr. Cat. 2; R60\nCarc. Cat. 2; R45\nT; R48/23\nT\nR: 45-48/23-60\nS: 45-53\nE\n050-008-00-3\ntributyltin compounds, with the exception of those specified elsewhere in this annex\n—\n—\nRepr. Cat. 2; R60-61\nT; R25-48/23/25\nXn; R21\nXi; R36/38\nN; R50-53\nT; N\nR: 21-25-36/38-48/23/25-50/53-60-61\nS: 45-53-60-61\nT; R25: C ≥ 2,5 %\nXn; R22: 0,25 % ≤ C < 2,5 %\nXn: R21: C ≥ 1 %\nT; R48/23/25: C ≥ 1 %\nXn; R48/20/22: 0,25 % ≤ C < 1 %\nXi; R36/38: C ≥ 1 %\nN; R50-53: C ≥ 2,5 %\nN; R51-53: 0,25 % ≤ C < 2,5 %\nR52-53: 0,025 % ≤ C < 0,25 %\nA\n1\n603-102-00-9\n1,2-epoxybutane\n203-438-2\n106-88-7\nF; R11\nCarc. Cat. 3; R40\nXn; R20/21/22\nXi; R36/37/38\nF; Xn\nR: 11-20/21/22-36/37/38-40-\nS: (2-)9-16-29-36/37-46\n603-197-00-7\ntebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol\n403-640-2\n107534-96-3\nRepr. Cat. 3; R63\nXn; R22\nN; R50-53\nXn; N\nR: 22-50/53-63\nS: (2-)22-36/37-60-61\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C <25 %\nR52-53: 0,25 % ≤ C < 2,5 %\n606-054-00-7\nisoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone\n—\n141112-29-0\nRepr. Cat. 3; R63\nN; R50-53\nXn; N\nR: 50/53-63\nS: (2-)36/37-60-61\nN; R50-53: C ≥ 2,5 %\nN; R51-53: 0,25 % ≤ C < 2,5 %\nR52-53: 0,025 % ≤ C < 0,25 %\n607-197-00-8\nnonanoic acid\n203-931-2\n112-05-0\nXi; R36/38\nN; R51-53\nXi; N\nR: 36/38-51/53\nS: (2-)46-61\n613-042-00-5\nimazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole\n252-615-0\n35554-44-0\nCarc. Cat. 3; R40\nXn; R20/22\nXi; R41\nN; R51-53\nXn; N\nR: 20/22-40-41-51/53\nS: (2-)26-36/37/39-46-61\n613-057-00-7\ndodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine\n216-474-9\n1593-77-7\nRepr. Cat. 3; R63\nC; R34\nR43\nN; R50-53\nC; N\nR: 34-43-50/53-63\nS: (1/2-)26-28-36/37/39-45-60-61\nC; R34: C ≥ 10 %\nXi; R36/37/38: 5 % ≤ C < 10 %\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C < 25 %\nR52-53: 0,25 % ≤ C < 2,5 %\n613-133-00-X\netridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole\n219-991-8\n2593-15-9\nCarc. Cat. 3; R40\nXn; R22\nR43\nN; R50-53\nXn; N\nR: 22-40-43-50/53\nS: (2-)36/37-46-60-61\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C < 25 %\nR52-53: 0,25 % ≤ C < 2,5 %\n613-149-00-7\npyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one\n405-700-3\n96489-71-3\nT; R23/25\nN; R50-53\nT; N\nR: 23/25-50/53\nS: (1/2-)36/37-45-60-61\nN; R50-53: C ≥ 0,025 %\nN; R51-53: 0,0025 % ≤ C < 0,025 %\nR52-53: 0,00025 % ≤ C < 0,0025 %\n(b) the following entries are inserted in accordance with the order of the entries set out in Table 3.2:\nIndex No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nConcentration Limits\nNotes\n019-003-00-3\npotassium (E,E)-hexa-2,4-dienoate\n246-376-1\n24634-61-5\nXi; R36\nXi\nR: 36\nS: (2-)25-46\n604-092-00-9\nphenol, dodecyl-, branched [1];\nphenol, 2-dodecyl-, branched;\nphenol, 3-dodecyl-, branched;\nphenol, 4-dodecyl-, branched;\nphenol, (tetrapropenyl) derivatives [2]\n310-154-3 [1]-[2]\n121158-58-5 [1]\n74499-35-7 [2]\nC; R34\nN; R50-53\nC; N\nR: 34-50/53\nS: (1/2-)26-36/37/39-45-61\nN; R50-53: C ≥ 2,5 %\nN; R51-53: 0,25 % ≤ C < 2,5 %\nR52-53: 0,025 % ≤ C < 0,25 %\n606-148-00-8\ncarvone (ISO);\n2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]\nd-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]\nl-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]\n202-759-5 [1]\n218-827-2 [2]\n229-352-5 [3]\n99-49-0 [1]\n2244-16-8 [2]\n6485-40-1 [3]\nR43\nXi\nR: 43\nS: (2-)24-37\n606-149-00-3\ntembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione\n335104-84-2\nRepr. Cat. 3; R63\nXn; R48/22\nR43\nN; R50-53\nXn; N\nR: 43-48/22-50/53-63\nS: (2-)36/37-46-60-61\nN; R50-53: C ≥ 0,25 %\nN; R51-53: 0,025 % ≤ C < 0,25 %\nR52-53: 0,0025 % ≤ C < 0,025 %\n607-707-00-9\nfenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate\n—\n71283-80-2\nXn; R48/22\nR43\nN; R50-53\nXn; N\nR: 43-48/22-50/53\nS: (2-)24-37-46-60-61\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C < 25 %\nR52-53: 0,25 % ≤ C < 2,5 %\n607-708-00-4\noctanoic acid\n204-677-5\n124-07-2\nC; R34\nN; R51-53\nC; N\nR: 34-51/53\nS: (1/2-)26-36/37/39-45-61\n607-709-00-X\ndecanoic acid\n206-376-4\n334-48-5\nXi; R36/38\nN; R51-53\nXi; N\nR: 36/38-51/53\nS: (2-)25-46-61\n607-710-00-5\n1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear\n271-093-5\n68515-50-4\nRepr. Cat. 2; R60-61\nT\nR: 60-61\nS: 53-45\n607-711-00-0\nspirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate\n—\n203313-25-1\nRepr. Cat. 3; R62-63\nXi; R36/37\nR43\nN; R50-53\nXn; N\nR: 36/37-43-50/53-62-63\nS: (2-)36/37-60-61\nXi; R43: C ≥ 0,1 %\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C < 25 %\nR52-53: 0,25 % ≤ C < 2,5 %\n607-712-00-6\ndodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate\n250-778-2\n31717-87-0\nRepr. Cat. 3; R63\nC; R34\nR43\nN; R51-53\nC; N\nR: 34-43-51/53-63\nS: (1/2-)26-28-36/37/39-45-61\nC; R34: C ≥ 10 %\nXi: R36/37/38: 5 % ≤ C < 10 %\n607-713-00-1\nfenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate\n—\n134098-61-6\nT+; R26\nXn; R22\nR43\nN; R50-53\nT+; N\nR: 22-26-43-50/53\nS: (1/2-)28-36/37-45-60-61-63\nN; R50-53: C ≥ 0,25 %\nN; R51-53: 0,025 % ≤ C < 0,25 %\nR52-53: 0,0025 % ≤ C < 0,025 %\n607-714-00-7\ntriflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate\n—\n126535-15-7\nCarc. Cat. 3; R40\nN; R50-53\nXn; N\nR: 40-50/53\nS: (2-)36/37-60-61\nN; R50-53: C ≥ 0,25 %\nN; R51-53: 0,025 % ≤ C < 0,25 %\nR52-53: 0,0025 % ≤ C < 0,025 %\n607-715-00-2\nbifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate\n442-820-5\n149877-41-8\nR43\nN; R50-53\nXi; N\nR: 43-50/53\nS: (2-)24-37-60-61\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C < 25 %\nR52-53: 0,25 % ≤ C < 2,5 %\n613-319-00-0\nimidazole\n206-019-2\n288-32-4\nRepr. Cat 2; R61\nXn; R22\nC; R34\nT; C\nR: 22-34-61\nS: 53-45\n613-320-00-6\nlenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione\n218-499-0\n2164-08-1\nCarc. Cat. 3; R40\nN; R50-53\nXn; N\nR: 40-50/53\nS: (2-)36/37-60-61\nN; R50-53: C ≥ 2,5 %\nN; R51-53: 0,25 % ≤ C < 2,5 %\nR52-53: 0,025 % ≤ C < 0,25 %\n616-213-00-2\nmandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide\n—\n374726-62-2\nN; R50-53\nN\nR: 50/53\nS: 60-61\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C <25 %\nR52-53: 0,25 % ≤ C < 2,5 %\n616-214-00-8\nmetosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide\n—\n139528-85-1\nCarc. Cat. 3; R40\nXn; R48/22\nN; R50-53\nXn; N\nR: 40-48/22-50/53\nS: (2-)36/37-46-60-61\nN; R50-53: C ≥ 0,025 %\nN; R51-53: 0,0025 % ≤ C < 0,025 %\nR52/53: 0,00025 % ≤ C < 0,0025 %\n616-215-00-3\ndimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide\n—\n163515-14-8\nXn; R22\nR43\nN; R50-53\nXn; N\nR: 22-43-50/53\nS: (2-)24-37-60-61\nN; R50-53: C ≥ 2,5 %\nN; R51-53: 0,25 % ≤ C < 2,5 %\nR52-53: 0,025 % ≤ C < 0,25 %\n616-216-00-9\nflonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide\n—\n158062-67-0\nXn; R22\nXn\nR: 22\nS: (2-)46\n616-217-00-4\nsulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide\n—\n946578-00-3\nXn; R22\nN; R50-53\nXn; N\nR: 22-50/53\nS: (2-)60-61\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C < 25 %\nR52-53: 0,25 % ≤ C < 2,5 %",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2015/1221/annex",
    "retrieved_at": "2026-11-01T14:46:34.183806+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}